论文部分内容阅读
目的:观察曲普瑞林预防子宫内膜异位症患者腹腔镜术后复发的疗效及安全性。方法:100例腹腔镜保守手术治疗子宫内膜异位症患者随机分为观察组与对照组,各组50例。观察组术后予曲普瑞林3.75mg皮下注射,每月1次;对照组予米非司酮10 mg,po qd。两组疗程均为3个月。观察两组患者疗效、复发情况及药品不良反应。结果:两组患者均手术成功。观察组患者疗效优于对照组,术后2年内复发率明显少于对照组(P<0.05),观察组停药1年后成功怀孕率明显高于对照组(P<0.05),不良反应发生率明显低于对照组(P<0.05)。结论:子宫内膜异位症患者腹腔镜保守手术后应用曲普瑞林可显著改善临床症状,有效降低术后复发率,且不良反应少,安全有效。
Objective: To observe the efficacy and safety of triptorelin in prevention of relapse after laparoscopy in patients with endometriosis. Methods: 100 cases of laparoscopic conservative surgery in patients with endometriosis were randomly divided into observation group and control group, 50 cases in each group. In the observation group, 3.75 mg of triptorelin was injected subcutaneously once a month after the operation. The control group was given mifepristone 10 mg po po. Two groups of treatment are 3 months. Efficacy, recurrence and adverse drug reactions in two groups were observed. Results: Both groups were successfully operated. The curative effect in observation group was better than that in control group, and the recurrence rate in 2 years after operation was significantly less than that in control group (P <0.05). The success rate of pregnancy in observation group was significantly higher than that in control group (P <0.05) The rate was significantly lower than that of the control group (P <0.05). Conclusion: The application of triptorelin after laparoscopic conservative surgery in patients with endometriosis can significantly improve clinical symptoms, effectively reduce the recurrence rate, and less adverse reactions, safe and effective.